FIELD: organic chemistry, biochemistry, pharmacy.
SUBSTANCE: invention relates to novel derivatives of aniline of the general formula (I): 
and their pharmaceutically acceptable salts and isomeric forms possessing properties of phosphodiesterase-4 inhibitors. Compounds can be used, fore example, for enhancing cognitive ability. In compounds of the general formula (I) R1 means linear or branched (C1-C4)-alkyl that can be unsubstituted or substituted with one or more halogen atoms; R2 means linear or branched (C1-C4)-alkyl that can be unsubstituted or substituted with one or more substitutes of the following order: halogen atom, (C1-C4)-alkoxy or their combinations, (C3-C10)-cycloalkyl, (C4-C16)-cycloalkylalkyl wherein alkyl fragment comprises from 1 to 4 carbon atoms, (C7-C11)-arylalkyl wherein aryl fragment comprises 6 carbon atoms, and alkyl fragment that can be linear or branched and comprises from 1 to 5 carbon atoms and wherein radical arylalkyl can be unsubstituted or substituted in aryl fragment with one or more substitutes of the following order: halogen atom, alkoxy group comprising from 1 to 4 carbon atoms or their combinations, and in alkyl fragment one group -CH2CH2- is optionally replaced for group -CH=CH-, and one group -CH2- is optionally replaced for -O- for -NH-, partially unsaturated carbocyclic group comprising from 5 to 9 carbon atoms that can comprise condensed benzene ring, heterocyclic group that can be saturated, partially saturated or unsaturated and comprises from 5 to 6 carbon atoms in cycle including one atom chosen from oxygen (O), or heterocyclylalkyl group wherein heterocyclic fragment can be saturated, partially saturated or unsaturated and comprises from 5 to 6 carbon atoms in cycle including 1-2 atoms chosen from nitrogen (N) or sulfur (S) atoms, and alkyl fragment that can be linear or branched comprises from 1 to 5 carbon atoms; R3 means partially unsaturated carbocyclylalkyl group wherein carbocyclic fragment comprises from 5 to 6 carbon atoms, and linear or branched alkyl fragment comprises from 1 to 5 carbon atoms, (C7-C11)-arylalkyl wherein aryl fragment comprises 6 carbon atoms, and linear or branched alkyl fragment comprises from 1 to 5 carbon atoms and wherein arylalkyl radical can be linear or substituted in aryl fragment with one or more substitutes of the following group: trifluoromethyl, (C1-C4)-alkyl, (C1-C4)-alkoxy or their combinations, heterocyclylalkyl group wherein heterocyclic fragment can be aromatic, partially or completely saturated and comprises from 5 to 10 atoms in cycle including 1-2 atoms chosen from N, O or S, and linear or branched alkyl fragment comprises from 1 to 5 carbon atoms and wherein heterocyclylalkyl group can be linear or substituted in heterocyclic fragment with one or more substitutes of the following order: halogen atom, (C1-C4)-alkyl, (C1-C4)-alkoxy or their combinations; R4 means (C6-C12)-aryl that can be linear or substituted with one or more substitutes of the following order: halogen atom, (C1-C4)-alkyl, (C2-C4)-alkenyl, hydroxy, (C1-C4)-alkoxy, (C2-C4)-alkoxyalkoxy, nitro, trifluoromethyl, -OCF3, amino group, aminoalkyl, aminoalkoxy, hydroxy-(C1-C4)-alkyl, hydroxamic acid, tetrazol-5-yl, 2-(heterocyclyl)-tetrazol-5-yl, carboxy, alkoxycarbonyl, cyano, acyl, alkylsulfonyl, phenoxy, trialkyloxy, R5-L or their combinations, or heteroaryl comprising from 5 to 10 atoms in cycle including 1-2 atoms chosen from N wherein heteroaryl can be linear or substituted with one or more substitutes of the following order: (C1-C4)-alkyl, (C1-C4)-alkoxy, carboxy, alkoxycarbonyl or their combinations; R5 means hydrogen atom, (C1-C8)-alkyl, (C3-C10)-cycloalkyl, C6-aryl, heterocyclic group that can be saturated, partially saturated or unsaturated and comprises from 5 to 10 atoms in cycle from which at least atom means N or O, and wherein heterocyclic group can be linear or substituted with one or more (C1-C4)-alkyls, or group heterocyclylalkyl, and others. Also, invention relates to intermediates compounds and to a method for enhancing the cognitive ability.
EFFECT: valuable biological and biochemical property of compounds.
49 cl, 8 sch, 26 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHOSPHODIESTARASE 4 INHIBITORS, CONTAINING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGUES | 2003 |
|
RU2368604C2 |
| INHIBITORS OF PHOSPHODIESTERASE 4 CONTAINING N-SUBSTITUTED DIARYLAMINE ANALOGUES | 2004 |
|
RU2388750C2 |
| PHOSPHODIESTERASE 4 INHIBITORS | 2003 |
|
RU2356893C2 |
| DERIVATIVES OF 4-(4-ALKOXY-3-HYDROXYPHENYL)-2-PYRROLIDONE AS PDE-4 INHIBITORS FOR TREATMENT OF NEUROLOGICAL SYNDROMES | 2002 |
|
RU2340600C2 |
| 6-AMINO-1H-INDAZOLE AND 4-AMINOBENZOFURAN COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS | 2003 |
|
RU2354648C2 |
| 1H-INDAZOLES, 1,2-BENZISOXAZOLES AND 1,2-BENZISOTHIAZOLES, SYNTHESIS THEREOF AND USE | 2004 |
|
RU2389729C2 |
| DERIVATIVES OF BENZIMIDAZOLE AND PHARMACEUTICAL COMPOSITIONS COMPRISING PRODRUG OF PROTON PUMP INHIBITOR | 1999 |
|
RU2232159C2 |
| LIGANDS OF NICOTINE RECEPTOR α, THEIR OBTAINING AND APPLICATION | 2005 |
|
RU2418797C2 |
| TYPE IV PHOSPHODIESTERASE INHIBITORS | 2004 |
|
RU2387646C2 |
| CONDENSED TRICYCLIC BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2689777C1 |
